SynOx Therapeutics raises €37M in Series A Financing
HealthCap and Medicxi co-lead, joined by Forbion and Gimv Financing to develop … Continue reading “SynOx Therapeutics raises €37M in Series A Financing”
HealthCap and Medicxi co-lead, joined by Forbion and Gimv Financing to develop … Continue reading “SynOx Therapeutics raises €37M in Series A Financing”
Proprietary biotech platform developing natural, non-animal leather material using patented Fine Mycelium™ … Continue reading “Novo Holdings participates in USD 45 million Series B investment in MycoWorks, creator of Reishi Fine Mycelium™ for luxury fashion and footwear brands”
Synendos Therapeutics (Synendos), a biopharmaceutical company developing a new class of small … Continue reading “Synendos Therapeutics Raises CHF 20 Million in Series A Financing”
Destiny Pharma plc (AIM:DEST) a clinical stage biotechnology company focused on the … Continue reading “Destiny Pharma to acquire Phase 3 ready C.difficile program and announces fund raising”
Biocomposites, an international medical devices company that engineers, manufactures and markets world … Continue reading “Transformational year for Biocomposites”
ValiRx (AIM: VAL) a clinical stage drug development company, announces today that … Continue reading “ValiRx enters agreement with Kalos Therapeutics”
Arix Bioscience plc (“Arix”, LSE: ARIX) a global venture capital company focused on investing … Continue reading “Arix Bioscience PLC: VelosBio to be acquired by Merck for $2.75 billion”
Novo Growth, the growth equity arm of Novo Holdings, an investment and … Continue reading “Novo Holdings leads EUR 22m Series A investment in The Protein Brewery, an innovative developer of protein-rich food ingredients”
Salvia BioElectronics B.V. (“Salvia”), a neurostimulation platform company targeting chronic migraine, announced … Continue reading “Salvia BioElectronics receives FDA Breakthrough Device Designation for innovative neurostimulation solution”
Transaction highlights Kiadis and Sanofi have reached conditional agreement on a recommended … Continue reading “Sanofi offers to acquire Kiadis for €308 million”
Synklino ApS, an emerging biotech company developing first-in-class breakthrough treatment to eliminate … Continue reading “Synklino Strengthens Management Team with Key Appointments”
NBE-Therapeutics, a Swiss-based company developing best-in-class cancer therapies based on its proprietary, … Continue reading “NBE-Therapeutics Commences First Clinical Study of Anti-ROR1 Antibody-Drug Conjugate for Patients with Solid Tumors”
F2G Ltd, a UK- and Austria-based biotech company developing novel therapies for … Continue reading “F2G Receives Second US FDA Breakthrough Therapy Designation for Olorofim”
Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), a pharmaceutical company developing … Continue reading “Futura provides regulatory and commercial update for MED3000”
STORM Therapeutics, the leading biotechnology company focused on the discovery and development … Continue reading “STORM Therapeutics selects first-in-class clinical candidate targeting METTL3”
Rappta Therapeutics (“Rappta”), focused on developing first-in-class anti-cancer drugs activating protein phosphatase … Continue reading “Rappta Therapeutics Raises Series A Financing for the Development of Phosphatase 2A drugs”
Backed by Omega Funds to develop new oral treatments for rare autoimmune diseases. … Continue reading “Chord Therapeutics launches with USD 16 million Series A financing from Omega Funds”
Novo Seeds, the early stage investment and company creation team of Novo … Continue reading “Novo Seeds co-leads Rappta Therapeutics Series A Financing for the Development of Phosphatase 2A drugs”
Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical … Continue reading “Verona Pharma to Present Phase 2b COPD Symptom and Quality of Life Data with Ensifentrine at CHEST 2020”
For more information about Optimum Strategic Communications, please get in touch
We'd love to hear from you...
GET IN TOUCH
© Copyright 2021 Optimum Strategic Communications All rights reserved.
Warnford Court
29 Throgmorton Street
London
EC2N 2AT
Tel: +44 (0)203 950 9144
Email: contact@optimumcomms.com
